| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 36,037 | 23,044 | ||
| Maturing in one year or less-USTreasury And Government | 154,098 | - | ||
| Maturing after one year through three years-USTreasury And Government | 54,939 | - | ||
| Maturing in one year or less-Corporate Debt Securities | 305,897 | - | ||
| Maturing after one year through three years-Corporate Debt Securities | 32,252 | - | ||
| Marketable securities | 547,186 | 607,293 | ||
| Accounts and other receivables | 90 | 90 | ||
| Prepaid and other current assets | 21,026 | 17,977 | ||
| Total current assets | 604,339 | 648,404 | ||
| Property and equipment, net | 4,829 | 4,392 | ||
| Operating lease right-of-use assets, net | 2,717 | 3,121 | ||
| Intangible assets | 27,190 | 27,190 | ||
| Other assets | 9,364 | 9,300 | ||
| Total assets | 648,439 | 692,407 | ||
| Accounts payable | 4,267 | 2,073 | ||
| Accrued expenses | 39,715 | 28,424 | ||
| Current portion of operating lease liabilities | 1,553 | 1,536 | ||
| Current portion of other long-term liabilities | 930 | 930 | ||
| Total current liabilities | 46,465 | 32,963 | ||
| Long-term portion of operating lease liabilities | 1,068 | 1,495 | ||
| Other long-term liabilities | 2,543 | 2,543 | ||
| Convertible preferred stock, .01 par value 3,000,000 shares authorized no shares issued and outstanding at june 30, 2025 and december 31, 2024 | - | 0 | ||
| Total liabilities | 50,076 | 37,001 | ||
| Common stock, .001 par value 297,000,000 shares authorized 66,446,846 and 66,374,549 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 66 | 66 | ||
| Additional paid-in capital | 2,327,196 | 2,317,621 | ||
| Accumulated other comprehensive income | 3,765 | 3,339 | ||
| Accumulated deficit | -1,732,664 | -1,665,620 | ||
| Total stockholders' equity | 598,363 | 655,406 | ||
| Total liabilities and stockholders' equity | 648,439 | 692,407 | ||
Celldex Therapeutics, Inc. (CLDX)
Celldex Therapeutics, Inc. (CLDX)